For years, I have been on a quiet mission: to self-advocate for my mental health and to reduce my reliance on pharmaceuticals to the absolute minimum. This was never about rejecting medicine outright—I have seen its power, and I am grateful for it. It was about reclaiming agency. It was about asking, with every prescription, a question that I am increasingly concerned fewer people are asking: Do I actually need this? And if I stop, what then?
Lately, I have noticed something unsettling. The medical field, as I observe it, is shifting away from teaching actionable, sustainable lifestyle methods and toward prescriptions as the default answer. And nowhere is this more visible—or more alarming—than in the meteoric rise of drugs like Ozempic and Wegovy.
These medications were originally developed to treat type 2 diabetes. But when patients and then the media realized they also produced rapid, dramatic weight loss, they became household names. Today, according to 2025 prescription data, over 97% of weight loss prescriptions for GLP-1 agonists are now privately issued, and the majority of users are not diabetic—they are using it specifically for weight loss or prediabetes prevention.
And here is the part that should give us pause: these are not one-time treatments. They are chronic, monthly costs. One analysis described them as akin to a mortgage, a gym membership, or a childcare expense. This is not healthcare as we once understood it. This is a subscription.
The Subscription Model Arrives in Healthcare
Historically, even in private healthcare, the expectation has been binary: you pay for a procedure, and then you are done. A hip replacement is a one-off. A cataract operation solves the issue for life. Laser eye surgery is typically performed once.
GLP-1 medications have disrupted this entirely. As one healthcare analysis put it, “Ozempic and Mounjaro require long-term, uninterrupted use to maintain weight loss. When patients stop, the weight often returns”. This creates a new psychology, one where people begin factoring healthcare into their monthly budgets—perhaps for the first time. It is a shift from curing to managing, from fixing to financing.
The pharmaceutical industry has noticed. Novo Nordisk, the maker of Wegovy, has launched a subscription program for self-pay patients, promising a “lower, predictable monthly price” in exchange for a 12-month commitment. Jamey Millar, the company's executive vice president of U.S. operations, was candid about the goal: “We want patients to stay with therapy over time, and that's what this subscription model encourages”.
GoodRx has launched GoodRx Companion, a $14.99-per-month subscription that bundles access to generic medications, online care, and discounts on routine services. Amazon Pharmacy's RxPass offers Prime members access to 60 prescription medications for a flat $5 per month. A 2025 study found that RxPass subscribers had 27% more medication on hand and were 29% more likely to refill their prescriptions.
On one level, this is access. On another, it is a quiet redefinition of what it means to be healthy—from a state you cultivate to a service you purchase.
The High Cost of the Subscription
The financial numbers are staggering. Ozempic's retail price without insurance ranges from $900 to $1,300 per month. Wegovy's self-pay price is currently $345 per month for the pen and $299 for the pill. Even with subscription discounts, the cost remains hundreds of dollars monthly.
Insurers are struggling. With list prices of roughly $1,000 a month, public and private payers are scrambling to keep up with ballooning demand, and in some cases are eliminating or restricting coverage entirely. North Carolina Medicaid plans to end GLP-1 coverage for weight loss. Pennsylvania is planning to limit coverage to beneficiaries at the highest risk.
The financial burden falls hardest on patients. One in five adults have been prevented from filling a prescription due to cost. One in ten have cut pills in half or skipped doses to manage expenses. For GLP-1 users, the situation is particularly acute. Researchers are beginning to see that “GLP-1 drugs are becoming the first-line obesity medication treatment,” and that it is “potentially a lifelong treatment”. But nearly 65% of patients discontinue them within the first year. When they stop, the weight often returns.
The Dependency We Do Not Talk About
The term “lifelong treatment” sounds clinical and neutral. But what it really means is dependency. These drugs work while people take them, but the benefits evaporate when treatment stops. One NYT opinion piece put it bluntly: “Even without enough knowledge about the ramifications of long-term use, it seems people may have to stay on semaglutide drugs indefinitely to keep weight off”.
A study from 2022 showed that patients regained two-thirds of the weight they had lost a year after quitting—even after embracing healthier lifestyles while on the medications. Another study found that three-quarters of patients stop GLP-1 medications within two years. And one of the most common reasons? Patients simply do not want to take a weight loss medication indefinitely.
There are physical risks, too. Up to 40% of weight lost on GLP-1 medications is lean muscle mass, which increases the risk of sarcopenia, osteoporosis, and metabolic dysfunction. A recent NEJM article noted that “questions remain about long-term adherence, weight regain after discontinuation of treatment, and the functional implications of the loss of muscle and bone mass”.
This is the hidden cost of the subscription model: you are not just paying with your money. You are paying with your muscle, your metabolic health, and your autonomy.
The Lifestyle Question No One Wants to Answer
What troubles me most is not the existence of these drugs. It is the growing sense that they are being positioned as replacements for lifestyle changes, rather than adjuncts to them.
Experts caution that medication alone is not the answer. “The biggest mistake people make with GLP-1 medications is thinking the prescription is the treatment,” said Dr. Katherine Saunders, an obesity medicine expert at Weill Cornell Medicine. The effects of the drugs are larger and last longer when they are combined with lifestyle changes.
But in practice, how many patients are receiving that guidance? One commentary noted that “if someone is diagnosed with high blood pressure or high cholesterol and then starts a medication, do they ease up on lifestyle changes like improving their diet or exercising more?” The evidence suggests the answer is often yes.
We are increasingly seeing a healthcare system based on treatment rather than prevention. As one pharmacist put it, “The pharmaceutical industry doesn't want you to know that if you ate the right food, you wouldn't need their drugs”. This is not a conspiracy theory. It is a recognition of incentive structures. A system that profits from lifelong subscriptions has little reason to invest in teaching people how to cancel their subscriptions.
The Scary Part: What Happens When the Subscription Ends?
This is where the subscription analogy becomes genuinely frightening. When you subscribe to a streaming service and it raises its price, you can cancel. When a product you use is discontinued, you find an alternative. But when your health depends on a subscription, you are in a different kind of trap.
What happens if the price of these drugs doubles? What if insurance coverage vanishes entirely? What if a supply shortage occurs, as it already has? What if new side effects emerge after a decade of use, as they often do?
The ICER report on weight loss medications concluded that they are cost-effective but create significant budget impact, and that managed care organizations “should expect value but not near-term cost savings”. In other words, they are valuable, but they are expensive. And when budgets get tight, subscriptions get cut.
Meanwhile, the alternatives—healthy diet, exercise, adequate sleep, stress management—are not subject to price hikes. They are not dependent on insurance coverage. They do not require a monthly payment. They are not at risk of supply shortages. They do not have undiscovered long-term side effects.
The Path Forward: Reclaiming Agency
I am not here to tell anyone to stop taking their medication. That would be irresponsible and dangerous. What I am saying is this: if the only way you can remain healthy is through pharmaceuticals, then you have traded your health for a subscription. And that is a trade I am not willing to make.
This means asking hard questions. Do I need this medication, or do I need to change my lifestyle? Can I work with my doctor to reduce my dosage over time? What alternatives exist that do not require a monthly payment? Am I being offered the tools to cultivate lasting health, or am I being sold a recurring expense?
The answers will be different for everyone. Some conditions genuinely require lifelong medication. But for many of the conditions now being treated with GLP-1s and similar drugs, lifestyle interventions are not just alternatives—they are the foundation upon which everything else should be built.
As one expert noted, a focus on lifestyle factors should replace the focus on treatments. This is not about guilt or shame. It is about empowerment. It is about recognizing that your health is not something you rent. It is something you build.
A Personal Note
I have spent years learning to self-advocate, to question prescriptions, to explore alternatives, to build a life that supports my mental health without relying on a monthly pill or injection. It has not been easy. It has required discipline, education, and the willingness to have uncomfortable conversations with doctors.
But the freedom it has given me—the knowledge that my health is not dependent on a corporation's pricing decisions—is worth every ounce of effort.
The subscription model is seductive because it promises convenience. But convenience is not the same as freedom. And a subscription is not the same as health.
So I will keep asking the questions. I will keep seeking the alternatives. And I will keep advocating for a healthcare system that teaches people how to be well, not just how to pay for treatment. Because at the end of the day, your health is not a service to be purchased. It is a capacity to be cultivated.
Find me at:
YouTube : Gaming for Mental Health
---
Sources
1. Bluefin Vision (2025). Appetite for Change: How Weight Loss Drugs Are Redefining Private Healthcare in the UK. Discusses the shift from one-off interventions to chronic monthly costs, the psychology of healthcare budgeting, and GLP-1 prescription data showing over 97% privately issued.
2. Today.com (2026). New Subscription Program for Wegovy Could Save Patients $1,200 a Year. Details Novo Nordisk's subscription model for Wegovy, executive commentary on encouraging long-term adherence, and pricing structures.
3. Medical Economics (2025). Do subscription services for drugs actually work? Reports on Amazon Pharmacy's RxPass study showing 27% more medication on hand and 29% higher refill rates among subscribers.
4. Medical Economics (2026). Is the online GLP-1 boom prioritizing profit over patients? Discusses virtual care subscriptions, monitoring gaps, and the shift away from patient-centered care.
5. Journal of Managed Care & Specialty Pharmacy (2026). ICER report demonstrates both the value and challenges in financing of weight loss medications. Concludes that weight loss medications are cost-effective but create significant budget impact; recommends integrating lifestyle management programs.
6. HealthLeaders Media / KFF Health News (2025). As Insurers Struggle with GLP-1 Drug Costs, Some Seek to Wean Patients Off. Reports on $1,000/month list prices, insurer coverage restrictions, and North Carolina Medicaid ending GLP-1 coverage.
7. American Family Physician (2026). Long-Term Use of Obesity Management Medications: Challenges and Discontinuation Strategies. Notes nearly 65% of patients discontinue within the first year, with weight regain common after cessation.
8. Bloomberg (2024). Weight-Loss-Drug Users Pay Up for Help Ditching the Pricey Meds. Reports on 2022 study showing patients regained two-thirds of weight lost after quitting GLP-1s, even with lifestyle changes.
9. BMJ Blogs / Journal of Medical Ethics (2026). The hidden cost of miracle cures. Notes that GLP-1 benefits depend on long-term commitment and evaporate when treatment stops.
10. NEJM (2026). GLP-1 Receptor Agonists. Raises questions about long-term adherence, weight regain after discontinuation, and functional implications of muscle and bone mass loss.
11. BMJ (2026). Shaping the UK's long term relationship with tirzepatide. Reports that up to 40% of weight lost on GLP-1 medications is lean body mass, risking sarcopenia and metabolic dysfunction.
12. Associated Press (2026). As demand for GLP-1 pills and shots surges, healthy habits are still key. Features expert commentary that medication alone is not the answer and must be combined with lifestyle changes.
13. NYT Opinion (2023). We Know How to Put People on Ozempic. Do We Know How to Get Them Off It? Notes that people may have to stay on semaglutide drugs indefinitely to keep weight off.
14. Drug Topics (2026). Drugs or lifestyle changes? Are pharmacists pill-happy? Advocates for a healthcare system based on prevention rather than treatment.
15. BBC (2026). Hertfordshire pharmacist wants to reduce reliance on medication. Quotes pharmacist on pharmaceutical industry incentives regarding diet and lifestyle.
16. The Incidental Economist (2025). Health Care Subscriptions: Who Benefits and Who Gets Left Behind? Raises concerns about pricing power, reduced competition, and long-term affordability of subscription-based healthcare.
Comments
Post a Comment